Search

ANTIBIOTIC EXPOSURE AND INTERPERSONAL VARIANCE MASK THE EFFECT OF IVACAFTOR ON RESPIRATORY MICROBIOTA COMPOSITION

Publication date: Available online 15 October 2017 Author(s): Anton Y. Peleg, Jocelyn Choo, Katherine Langan, Deirdre Edgeworth, Dominic...

Vertex Touts Positive Triple-Drug Data For Cystic Fibrosis Patients

VERTEX TOUTS POSITIVE TRIPLE-DRUG DATA FOR CYSTIC FIBROSIS PATIENTS

Vertex Pharmaceuticals continued its march away from being the biggest loser in the hepatitis C wars and toward increasing dominance...

 
 
 
FDA Approves Ivacaftor Drug for Cystic Fibrosis: More Patients to Benefit

FDA APPROVES IVACAFTOR DRUG FOR CYSTIC FIBROSIS: MORE PATIENTS TO BENEFIT

The US FDA has allowed the use of ivacaftor for 23 additional mutations in cystic fibrosis patients, thereby allowing more patients...

 
 
 
Vertex Bags Concert's Rival CF Drug For $160M, Plans Combo Studies

VERTEX BAGS CONCERT'S RIVAL CF DRUG FOR $160M, PLANS COMBO STUDIES

Concert Pharmaceuticals has been plugging away with an experimental cystic fibrosis drug that, if successful, might someday pose a...

 
 
 
 
 
 

EFFECT OF BRONCHODILATORS IN HEALTHY INDIVIDUALS RECEIVING LUMACAFTOR/IVACAFTOR COMBINATION THERAPY

Publication date: Available online 25 November 2016 Author(s): Gautham Marigowda, Fang Liu, David Waltz In an open-label, single-center...